Answers are grounded in this paper and cite their sources.
COVID-19 has rapidly spread all over the world, progressing into a pandemic. This situation has urgently impelled many companies and public research institutes to concentrate their efforts on research for effective therapeutics. Here, we outline the strategies and targets currently adopted in developing a vaccine against SARS-CoV-2. Based on previous evidence and experience with SARS and MERS, the primary focus has been the Spike protein, considered as the ideal target for COVID-19 immunotherapies.
No takes yet. Share an insight, caveat, or question.
Salvatori et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: